19. Treatment of chronic hepatitis C genotype 1 with ledipasvir and sofosbuvir in CKD ESRD patients on dialysis

Yattoo, Ghulam Nabi; Dar, Gulzar Ahmad; Gulzar, Ghulam Mohammad; Sodhi, Jaswinder Singh; Kawoosa, Zaffar

doi:10.1016/j.jceh.2018.06.310

Cited by 8 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, scattered data from small cohorts suggest a high SVR12 without significant adverse effects. 25,26 Therefore, both EASL and AASLD/IDSA guidelines acknowledge that treatment can be considered during pregnancy, or continued in the case of accidental conception during treatment, on a case-by-case basis, with a multidisciplinary approach and after a discussion with the patient about the potential risks and benefits. 20,21 Expanding the use of DAAs during pregnancy would be crucial to reduce the burden of perinatal transmission.…”

Section: Prevention Of Perinatal Transmissionmentioning

confidence: 99%

Management of Hepatitis C in Children and Adolescents: An Update

Rubino,

Indolfi,

Foster

2024

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Section: Prevention Of Perinatal Transmissionmentioning

confidence: 99%

Management of Hepatitis C in Children and Adolescents: An Update

Rubino,

Indolfi,

Foster

2024

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

“…Yattoo et al reported 15 HCV positive, non-cirrhotic, pregnant Indian women who received sofosbuvir/ledipasvir during their second-early third trimesters to complete a 12-week course of therapy. SVR was achieved by all women without safety issues, and newborns were delivered without any adverse events ( 13 ).…”

Section: The Double Benefit Of Treating Hepatitis During Pregnancymentioning

confidence: 99%

Viral hepatitis management in pregnancy: practical insights from a pediatric perspective

Rubino,

Stinco,

Indolfi

2024

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

“…Several additional case reports and small case series report intentional DAA treatment starting at the second or third trimester of pregnancy with 100% SVR12 in mothers completing therapy and no cases of vertical transmission [56,102,103]. Abdallah et al [104 & ] reported first trimester DAA exposure in 100 women who became pregnant while on DAA, with no obvious maternal or foetal safety signal observed.…”

Section: Direct-acting Antiviral Treatment For Prevention Of Paediatr...mentioning

confidence: 99%

Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children

Honegger

Gowda

2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewDirect-acting antiviral (DAA) regimens targeting hepatitis C virus (HCV) are now approved for young children. This review examines recent DAA experience in children, current treatment recommendations and challenges, and potential treatment-as-prevention strategies.Recent findingsIn 2021, the US FDA extended approval of two pan-genotypic DAA regimens, glecaprevir/pibrentasvir and sofosbuvir/velpatasvir, to children as young as age 3 years based on high success rates and reassuring safety profiles in registry trials. Similar performance has been replicated with real-world DAA use in thousands of adolescents and in limited reports of children with high-risk conditions, including cirrhosis, cancer, thalassemia and HIV-coinfection. Treatment without delay is now recommended in the USA for viremic children aged 3 years and up to prevent disease progression and future spread. To date, treatment expansion is limited by high rates of undiagnosed paediatric infection. Universal prenatal screening will aid identification of perinatally exposed newborns, but new strategies are needed to boost testing of exposed infants and at-risk adolescents. Postpartum treatment programmes can prevent subsequent vertical transmission but are hampered by low rates of linkage to care and treatment completion. These challenges may be avoided by DAA use in pregnancy, and this warrants continued study.SummaryPaediatric HCV is now readily curable. Substantial clinical and public health effort is required to ensure widespread uptake of this therapeutic breakthrough.

show abstract

19. Treatment of chronic hepatitis C genotype 1 with ledipasvir and sofosbuvir in CKD ESRD patients on dialysis

Cited by 8 publications

References 0 publications

Management of Hepatitis C in Children and Adolescents: An Update

Management of Hepatitis C in Children and Adolescents: An Update

Viral hepatitis management in pregnancy: practical insights from a pediatric perspective

Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children

Contact Info

Product

Resources

About